24TOPNEWSFinancial IntelligenceBETA中文
← Overview
Healthcare · 13.1

Pharmaceuticals

Quantified news impact based on deduplicated, quality-reviewed events in a single 60-day window.

Average net impact+25weighted per event
Average gross impact31absolute weighted average
Events23same period
Confidence81%model average
Raw intensity62before weighting
Previous period0net impact
Gross changeInsufficient base
Diffusion speed0.4 / day
Concentration6%
Direction disagreement18%
Source independence97%14 sources
IMPACT TREND

60-day effective impact

Positive 19 · Negative 2 · Mixed 2

Current periodPrevious period
TIME HORIZON

Impact duration

Immediate0%0 cumulative effective impact
Short term44%310 cumulative effective impact
Medium term49%344 cumulative effective impact
Long term7%48 cumulative effective impact
CO-IMPACT

Related industries

13.3Biotechnology13 shared events+3010.1Semiconductor Value Chain3 shared events+3913.15Pharmaceutical R&D Services3 shared events+1813.2Traditional Chinese Medicine3 shared events+171.14Batteries & Energy Storage2 shared events+368.3New Energy Vehicles2 shared events+361.11Wind & Solar Equipment2 shared events+3410.5Robotics2 shared events+31
EVENT EVIDENCE

Events ranked by effective impact

Page 1 of 3 · 23 events

Macro1
01
Macropositive

China's Goods Trade Exceeds RMB 25 Trillion in First Half of 2026, New Three Exports Top RMB 800 Billion

China's goods trade reached RMB 25.47 trillion in the first half of 2026, up 16.9% year-on-year, the first time exceeding RMB 25 trillion for the period. Imports hit RMB 10.74 trillion, up 22.1%. Exports of the 'new three' products — electric vehicles, lithium batteries, and solar cells — totaled RMB 819.64 billion, up 46.1%. Private enterprises accounted for 57% of trade value. The data underscores China's continued dominance in global goods trade.

Effective
+57
Intensity
80
Confidence
90%
Horizon
Short term
Industries4
01
Industriespositive

China's Innovative Drug Out-Licensing Hits 81 Deals ~$110 Billion in H1 2026; 38 Class 1 Drugs Approved

In the first half of 2026, China's innovative drug out-licensing reached 81 deals valued at about $110 billion, already 80% of the full-year 2025 total. Meanwhile, 38 Class 1 innovative drugs were approved for market, including 11 with new targets and mechanisms, all domestically developed. Chinese companies accounted for eight of the top ten global pharmaceutical deals, and total deal value represented about 70% of global M&A. The period also saw the first AI-discovered drug enter Phase III trials in China.

Effective
+60
Intensity
85
Confidence
90%
Horizon
Medium term
02
Industriespositive

China Insurance Association Completes Drug Selection for Commercial Insurance List; NHSA to Expand Innovative

The China Insurance Association, under the National Financial Regulatory Administration, has completed preliminary drug selection for its commercial insurance drug list, which is pending release. The list differs from the NHSA's commercial insurance innovative drug list and is for pure commercial health insurance. In 2026, the NHSA will expand its innovative drug list for the first time, requiring drugs with strong insurance suitability. Submissions for the NHSA list in 2026 are less than half of 2025. The first NHSA list faced challenges in Huiminbao products, including incomplete discount channels. Alzheimer's drugs lecanemab and donanemab entered national medical insurance in 2026 and are in multiple Huiminbao products. The China Insurance Association is also developing a drug guarantee list to standardize commercial insurance drug lists.

Effective
+57
Intensity
80
Confidence
90%
Horizon
Short term
03
Industriesnegative

Record-Scale 12th National Drug Volume-Based Procurement Opens, Introduces 'Zero-Volume Award' Mechanism

The 12th round of China's national volume-based drug procurement opened on July 31 in Shanghai, covering 65 commonly used clinical varieties across hypertension, diabetes, oncology, transplant anti-rejection, and anti-infection areas, making it the largest batch since the program began. A total of 495 companies submitted 859 product bids. The round introduced a 'zero-volume award' mechanism to curb extreme low pricing, and extended the contract period to three years. Over 45,000 medical institutions submitted procurement demand volumes.

Effective
-47
Intensity
72
Confidence
85%
Horizon
Medium term
04
Industriespositive

China COVID-19 Positivity Rate Hits 16.3% in Week 29 of 2026; Drug Demand Rises for Junshi Biosciences and

China's COVID-19 positivity rate reached 16.3% in week 29 of 2026, up from low levels in the prior week, according to the Chinese Center for Disease Control and Prevention. The virus is at a medium epidemic level overall, with the highest rate among those aged 15-59. In response, Junshi Biosciences and Simcere reported rising demand for their antiviral drugs. Junshi saw a rapid increase in orders from late June, while Simcere's online platform orders grew 48.2% week-on-week, with Shanghai accounting for 22.66% of JD. com orders.

Effective
+30
Intensity
70
Confidence
80%
Horizon
Short term
Companies5
01
Companiespositive

Argenx to Acquire Forte Biosciences for $2.2 Billion in Cash, a 40.5% Premium, Gaining Anti-CD122 Asset FB102

Argenx announced on July 27, 2026, an all-cash acquisition of Forte Biosciences for approximately $2.2 billion, or $77 per share, a 40.5% premium over the prior close. The deal, Argenx's first since its Nasdaq listing, targets FB102, an anti-CD122 antibody modulating IL-12/IL-15 signaling. Phase 1b data for FB102 showed statistically significant benefits in celiac disease and vitiligo, with no serious adverse events.

Effective
+51
Intensity
78
Confidence
85%
Horizon
Medium term
03
Companiespositive

CSPC Pharmaceutical Group Expects Interim Profit of RMB5.9-6.2 Billion, Up 132%-143%

CSPC Pharmaceutical Group issued a profit alert, expecting interim profit attributable to shareholders of approximately RMB5.9 billion to RMB6.2 billion, a year-on-year increase of 132% to 143%. The surge was driven by a sharp rise in licensing fee revenue, including US$840 million in upfront payments recognized in the second quarter. Additionally, the group's finished drug business saw sales revenue rise about 10% year-on-year, supporting overall profitability.

Effective
+44
Intensity
80
Confidence
90%
Horizon
Short term
04
Companiespositive

InnoCare Pharma’s TYK2 Inhibitor ICP-488 Meets Primary Endpoint in Phase III Psoriasis Study

InnoCare Pharma announced that its novel TYK2 inhibitor Fadeucravacitinib (ICP-488) met the primary endpoint in a Phase III registrational study for moderate to severe plaque psoriasis. The randomized, double-blind, placebo-controlled, multicenter trial showed highly statistically significant and clinically meaningful improvement, with consistent benefits across multiple secondary endpoints. Safety results were consistent with prior studies, with no new safety signals identified. Detailed data will be presented at international medical conferences or published in peer-reviewed journals.

Effective
+39
Intensity
70
Confidence
90%
Horizon
Medium term
05
Companiespositive

Huarun Double-Crane to Acquire 23.5% Stake in Lier Chemical for RMB 5.656 Billion, Becoming Actual Controller

Huarun Double-Crane plans to acquire a 23.5% stake in Lier Chemical from Jiuyuan Group and Huacai Technology for RMB 5.656 billion, or RMB 30.07 per share. The deal will make China Huarun Co. , Ltd. the actual controller of Lier Chemical. The acquisition follows a public solicitation process in which Huarun Double-Crane was selected as the top bidder. Lier Chemical, a major pesticide producer, will provide a platform for Huarun's synthetic biology industrialization.

Effective
+29
Intensity
60
Confidence
70%
Horizon
Medium term